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Abstract
Leiomyosarcoma (LMS) is a soft tissue tumor with a significant degree of morphologic and 
molecular heterogeneity. We employed integrative molecular profiling to discover and 
characterize molecular subtypes of LMS. Gene expression profiling was performed on 51 LMS 
samples. Unsupervised clustering demonstrated 3 reproducible LMS clusters. Array comparative 
genomic hybridization (aCGH) was performed on 20 LMS samples and demonstrated that the 
molecular subtypes defined by gene-expression showed distinct genomic changes. Tumors from 
the “muscle-enriched” cluster showed significantly increased copy number changes (p=0.04). 
Most muscle-enriched cases showed loss at 16q24 which contains FANCA, known to play an 
important role in DNA repair, and loss at 1p36 which contains PRDM16, whose loss promotes 
muscle differentiation. Immunohistochemistry was performed on LMS tissue microarrays (n=377) 
for five markers with high levels of mRNA in the muscle-enriched cluster (ACTG2, CASQ2, 
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SLMAP,CFL2, MYLK) and demonstrated significantly correlated expression of the 5 proteins (all 
pairwise p < 0.005). Expression of the 5 markers was associated with improved disease-specific 
survival (DSS) in a multivariate Cox regression analysis (p < 0.04). In this analysis that combined 
gene expression profiling, aCGH and immunohistochemistry, we characterized distinct molecular 
LMS subtypes, provided insight into their pathogenesis, and identified prognostic biomarkers.
Keywords
sarcoma; leiomyosarcoma; integrative genomics; gene expression profiling; array comparative 
genomic hybridization; tissue microarrays
Introduction
Cancer can be broadly divided into 3 main classes: leukemias/lymphomas (derived from 
cells of the hematopoetic system), carcinomas (derived from epithelial cells), and sarcomas 
(derived from mesenchymal tissues, including bone, muscle, and cartilage)(Abbas et al., 
2005). Within each of these broad categories, tumors have traditionally been further 
subdivided into specific diagnostic subtypes based primarily on their clinical and 
histopathological features (Ackerman and Rosai, 2004; Lakhani and Ashworth, 2001). In the 
past decade, gene expression profiling has been used to discover novel cancer subtypes in a 
variety of hematological (Alizadeh et al., 2000; Bullinger et al., 2004) and epithelial 
(Lapointe et al., 2004; Sorlie et al., 2001) malignancies. It is hoped that the further 
subclassification of cancer based on molecular features will facilitate the identification of 
prognostic and predictive biomarkers (Beck et al., 2009b; Sidransky, 2002), the 
development of therapies targeted at oncogenic pathways altered in particular subtypes 
(Potti et al., 2006), and ultimately, the application of a more personalized form of medicine 
to improve the lives of cancer patients (Sotiriou and Piccart, 2007).
Soft tissue sarcomas account for approximately 1% of all malignancies diagnosed annually, 
and there are ~100 recognized sarcoma diagnostic subtypes (Weiss and Goldblum, 2008). 
Sarcomas can be subdivided in 2 groups, one where each tumor type is characterized by a 
unique simple recurrent genetic abnormality such as a chromosomal translocation and the 
other where highly complex genetic abnormalities are present (Helman and Meltzer, 2003). 
Leiomyosarcomas (LMS) belong to the latter group and are malignant neoplasms of smooth 
muscle, which most frequently occur in the uterus or retroperitoneum but can occur 
throughout the body (Fletcher et al., 2002). They account for ~24% of soft tissue sarcomas, 
making LMS the most common soft tissue sarcoma subtype (Toro et al., 2006). While 
significant advances have been made in the molecular understanding of sarcoma subytpes 
with simple recurrent genetic abnormalities (Helman and Meltzer, 2003), the molecular 
pathogenesis and heterogeneity of LMS are poorly understood. Currently, the diagnosis of 
LMS is made based on the demonstration of smooth muscle differentiation in a 
histologically malignant neoplasm (Fletcher et al., 2002). Clinical management typically 
consists of surgery with adjuvant doxorubicin-based chemotherapy with consideration for 
the addition of ifosfamide and radiotherapy in selected cases (Borden et al., 2003). 
Doxorubicin-based chemotherapy has shown a marginal association with improved overall 
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survival (Cochrane Database Syst Rev, (2000)) and the addition of ifosfamide has been 
shown to strengthen the association with improved survival (Pervaiz et al., 2008). The 
overall prognosis for soft tissue sarcomas is poor, with reported rates of 12 year disease-
specific survival of 64% (Kattan et al., 2002). There are currently no effective targeted 
therapies available for LMS that are directed at molecular aberrations in specific LMS 
subtypes. It has been shown that gene expression signatures may be able to predict 
metastasis in LMS (Lee et al., 2004). Our laboratory has previously shown that macrophage 
infiltration correlates with poor outcome in LMS (Espinosa et al., 2009a; Lee et al., 2008). 
There are currently no molecular biomarkers utilized in the routine prognostication or 
determination of treatments in LMS.
In this study, we performed global gene expression analysis of 51 LMS samples to identify 3 
distinct LMS subtypes. We then performed array comparative genomic hybridization 
(aCGH) to characterize the genomic changes seen in 2 of the LMS subtypes. Based on our 
gene expression findings, we identified biomarkers for the most distinct LMS subtype and 
evaluated their pattern of expression and association with clinicopathologic variables by 
performing immunohistochemistry (IHC) on tissue microarrays (TMAs) containing 377 
LMS samples. In this integrative analysis, we characterized distinct molecular LMS 
subtypes, provided insight into their pathogenesis, and identified prognostic biomarkers.
MATERIALS AND METHODS
The 51 tumor samples were obtained from 46 patients (5 patients each contributed 2 
samples). Clinicopathologic features of these tumors are provided in Supporting Information 
Table 1. The studies were performed with the approval by the Institutional Review Board at 
Stanford University Medical Center.
Briefly, gene expression profiling was performed on 51 LMS samples using 44K spotted 
cDNA microarrays. To identify molecular subtypes, unsupervised hierarchical clustering 
and principal component analysis (PCA) were performed. To assess the reproducibility of 
the clusters in an independent dataset, the clusterRepro algorithm (Kapp and Tibshirani, 
2007) was utilized with the LMS samples from the GSE2553 dataset (Baird et al., 2005) 
used as the testing dataset. For 20 of the LMS samples containing gene expression data, 
aCGH was performed on 44k Agilent arrays. The fused lasso algorithm was applied to 
identify regions of copy number gain and loss (Tibshirani and Wang, 2008). To determine 
whether the gene-expression defined molecular subtypes could be accurately predicted 
based solely on aCGH changes, 3 classification techniques were used: Prediction Analysis 
of Microarrays (PAM) (Tibshirani et al., 2002), Prediction Analysis of Microarrays-
FusedLasso (PAM-FL) (See Supporting Information Materials and Methods for explanation 
of PAM-FL), and K nearest neighbor (KNN). IHC was performed on LMS TMAs using 
antibodies for ACTG2, CASQ2, SLMAP, CFL2, and MYLK, and the stains were scored by 
2 surgical pathologists (AHB and RBW). Additional information on the methods for gene 
expression profiling, aCGH, IHC, and statistical analysis are provided in the Supporting 
Information Materials and Methods. All IHC images used in this study are accesible from 
the accompanying website: http://tma.stanford.edu/tma_portal/LMS_IMP. In addition, gene 
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expression and aCGH data have been deposited in the Gene Expression Omnibus (Edgar et 
al., 2002) with accession number GSE17555.
Results
A. Gene Expression Profiling
Unsupervised hierarchical clustering was performed on median centered gene expression 
data using the 3038 gene spots that had a standard deviation (SD) of at least 1 across the 51 
LMS samples and passed quality-based filtering criteria (described in Supporting 
Information Materials and Methods). This analysis demonstrated 3 predominant clusters of 
LMS samples (Fig. 1A). Cluster 1 contained 13 samples derived from 11 patients, cluster 2 
contained 12 samples derived from 12 patients, and cluster 3 contained 26 samples derived 
from 23 patients (Supporting Information Table 1). For the 5 patients with paired primary, 
recurrent, and/or metastatic samples in the analysis, the matched pairs clustered into the 
same group (Fig. 1A), suggesting that the molecular subtype is preserved during metastasis, 
as has been observed in other malignancies (Bernards and Weinberg, 2002; Ramaswamy et 
al., 2003; Weigelt et al., 2005; Weigelt and van't Veer, 2004). To assess the similarity of 
each LMS sample to its cluster’s centroid, we defined a centroid for the 3 predominant LMS 
clusters and assessed the correlation of each LMS sample with each LMS group centroid. 
48/49 samples showed the highest correlation with the sample’s LMS group centroid, which 
provides further support of the clusters’ robustness (Fig. S1). Neither of the 2 “outlier” cases 
from unsupervised hierarchical cluster analysis showed strong correlation with any of the 
LMS group centroids (correlation < 0.35).
To visualize the variability within LMS by an additional unsupervised technique, we 
performed PCA, which demonstrated that the molecular subtypes observed in hierarchical 
clustering were largely captured in the first 2 principal components (Fig. 1B). To identify a 
sparse set of genes composing the first 2 principal components, we performed sparse PCA 
(Hui et al., 2006) and identified 45 genes in component 1 and 40 genes in component 2. 
Plotting the LMS samples along these 2 sparse principal components largely recreates the 
clustering structure observed in the hierarchical clustering analysis (Fig. 1C), and the 
classifications into three subtypes made using a simple nearest neighbor classifier based on 
these 2 principal components is concordant with the classifications made by unsupervised 
hierarchical clustering for 48/49 LMS samples (Fig. 1C).
Significance analysis of microarrays (SAM) (Tusher et al., 2001) was performed to identify 
sets of genes highly differentially expressed between the 3 LMS subtypes. The set of genes 
most highly and differentially expressed in LMS Group I was significantly enriched for 
functional annotation terms relating to muscle contraction and the actin cytoskeleton 
(including:CALD1, SLMAP, DMD, ACTG2, CASQ2,CFL2, MYLK, LPP) (Supporting 
Information Table 1). Since this gene set is highly enriched for genes encoding proteins 
involved in muscle differentiation and function, we refer to this LMS group as the ”Group I/
muscle-enriched” LMS molecular subtype. This gene set also showed significant enrichment 
for phosphoproteins, protein kinases, and kinase binding proteins (Supporting Information 
Table 1). The set of genes most highly and differentially expressed in LMS Group II was 
significantly enriched for functional annotation terms relating to protein metabolism, 
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regulation of cell proliferation, and organ development (Supporting Information Table 1). 
The set of genes most highly and differentially expressed in LMS Group III was 
significantly enriched for annotation terms relating to organ and system development, metal 
binding, extracellular proteins, proteins involved in the wound response, and ribosomal 
proteins involved in protein synthesis (Supporting Information Table 1). Of the 3 LMS 
subtypes, the Group III gene set contained the most genes (23) and highest proportion of 
genes from the CSF1 response gene expression signature (Beck et al., 2009a). In a prior 
study, the CSF1 response gene expression signature was shown to be present in a subset of 
LMS, and the expression of 4 CSF1 response signature associated proteins was associated 
with poor prognosis in LMS (Espinosa et al., 2009b).
To compare the pattern of gene expression seen in these LMS subtypes with other sarcomas, 
we performed unsupervised clustering of a large and diverse set of soft tissue tumors (STTs, 
n = 291, spanning 25 diagnostic subtypes) analyzed in our laboratory with the 51 LMS 
samples using the same gene list that was used above to cluster only the LMS samples. In 
this analysis, samples from the Group I/muscle-enriched cluster continue to cluster together, 
while cases from the other LMS clusters were interspersed in the dendrogram with other soft 
tissue tumor types (Fig. S2A). We performed sparse PCA on the same set of LMS and STT 
tumors and similarly found that the Group I/muscle-enriched LMS samples formed the most 
distinct cluster of LMS cases, while the other subtypes of LMS were intermixed with other 
STTs (Fig. S2B). These results suggest that of the three LMS subtypes, Group I/muscle-
enriched shows the most distinct and specific gene expression profile.
To evaluate the reproducibility of the LMS molecular subtypes in an independent dataset, 
we searched the Gene Expression Omnibus for publically available sarcoma gene expression 
datasets and identified 1 dataset containing greater than 15 LMS samples (Baird et al. 
(GSE2553) contains 17 LMS samples) (Baird et al., 2005). We utilized the clusterRepro 
algorithm (Kapp and Tibshirani, 2007) by training it on our LMS dataset and testing it on 
the Baird set of 17 LMS samples. In this analysis, 12 of the 17 Baird LMS samples were 
classified as Group I/muscle-enriched LMS, and the Group I LMS achieved statistically 
significant cluster reproducibility (IGP=1, p=0.03). Only 1 of 17 cases was classified as 
Group II and 4 of 17 cases were classified as Group III. Neither LMS Group II nor III 
achieved statistically significant reproducibility on this dataset (IGP < 0.5, p > 0.5). These 
findings suggest that the Group I/muscle-enriched LMS subtype is significantly reproducible 
in the Baird dataset, and most LMS cases from this dataset are best characterized as Group I/
muscle-enriched LMS (Fig. S3). Although the Baird dataset provides no definite support for 
group II or III LMS, this may be partially explained by the dataset’s relatively small number 
of LMS samples and the relatively low level of variability observed in the LMS samples in 
this dataset (Baird et al., 2005).
Information on patient age, tumor grade, tumor histological subtype, primary tumor site, 
tumor status (primary, recurrence, metastasis), and patient treatment were available for the 
LMS cases in the gene expression analysis (Supporting Information Table 1). There was no 
significant difference in patient age or tumor grade between the 3 molecular subtypes (p > 
0.15). Group I LMS tended to be conventional LMS histological subtype (8/11, 73%), 
Group II LMS were relatively evenly distributed between conventional (5/12, 42%) and 
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pleomorphic/mixed (7/12, 58%), and Group III LMS tended to be pleomorphic/mixed 
histological subtype (16/21, 76%) [p=0.03]. Group I LMS (10/11, 91% extra-uterine) and 
Group II LMS (9/12, 75% extra-uterine) tended to have an extra-uterine primary tumor site, 
while Group III LMS was relatively evenly distributed between uterine and extra-uterine 
primary sites (9/19, 47% extra-uterine) [p=0.04]. 9/13 Group I samples and 10/12 Group II 
samples analyzed by gene expression profiling were from the primary tumor site, while only 
6/23 Group III tumors were from the primary site [p=0.002] and the remainder came from a 
recurrence (7/23) or a metastasis (10/23). [Although there are a total of 24 Group III 
samples, the site for one of the samples (STT4401) was not known to be primary or 
metastasis/recurrence, and this sample was excluded from this analysis]. Information on 
patient treatment with radiotherapy and/or chemotherapy was available for 45 of the Group 
I, II, and III samples. There was no significant difference in proportion of treatment with 
radiotherapy and/or chemotherapy in the molecular subtypes: 11/13 Group I samples, 11/12 
Group II samples, and 14/20 Group III samples were resected from patients with no history 
of prior treatment with radiotherapy or chemotherapy (p = 0.3). 3 patients contributed tumor 
samples removed pre- and post-treatment with chemotherapy and/or radiotherapy, and in all 
3 cases the pre- and post-treatment samples clustered into the same LMS molecular subtype.
B. Array Comparative Genomic Hybridization (aCGH)
aCGH was performed to characterize genomic changes in 20 LMS samples and 4 normal 
smooth muscle samples: 12 of the LMS samples were from Group I/muscle-enriched 
(derived from 10 patients), 7 from Group III (derived from 6 patients), and 1 from Group II. 
To identify regions of genomic gain and loss, the fused lasso technique was performed 
(Tibshirani and Wang, 2008) with an FDR threshold of 10% for calling regions of gain/loss 
(Supporting Information Table 1).
The Group I/muscle-enriched and Group III LMS samples showed distinct patterns of 
genomic gain and loss. The Group I samples showed significantly increased genomic gains 
and losses compared to the Group III samples (mean proportion of genome involved by 
gain/loss = 17% in Group I samples vs. 2% in Group III samples, p=0.04) (Fig. 2). 
Analyzing the 7 Group III samples together showed no statistically significant shared 
regions of gain or loss (all consensus FDR > 5%). In contrast, analyzing the 12 Group I/
muscle-enriched samples together showed 691 spots that each had a consensus FDR < 5% 
(Supporting Information Table 1). Taken together, these findings suggest distinct pathways 
of oncogenesis in the 2 LMS subtypes, with decreased genomic stability in Group I/muscle-
enriched LMS.
Interestingly, loss of a 291 KB region on 16q24 was seen in 7 of 12 Group I/muscle-
enriched samples (all of which showed at least 7% genomic changes) and none of the Group 
II (0/1) or Group III (0/7) samples. This genomic region contains several cancer-associated 
genes, including the Fanconi anemia, complementation group A (FANCA) gene, which is a 
core Fanconi anemia protein that functions as a signal transducer and DNA-processing 
molecule in a DNA-damage repair network (Wang, 2007). In acute myeloid leukemia, it has 
been shown that acquired FANCA dysfunction promotes cytogenetic instability and clonal 
progression (Lensch et al., 2003). The loss of FANCA may be an important event that is 
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specific for the molecular pathogenesis of the Group I/muscle-enriched LMS subtype and 
suggests an etiology for the increased genomic complexity observed in this LMS subtype. In 
addition, this region contains CBFA2T3, which is known to be involved in a translocation 
with RUNX1 (AML1) in a subset of therapy related acute myeloid leukemia (Ottone et al., 
2009) and was identified as a putative breast tumor suppressor gene (Kochetkova et al., 
2002). The shared deleted region on 16q24 spans a total of 36 genes and includes CDK10, 
TCF25, FOXF1, and IRF8 in addition to FANCA, CBFA2T3 and others. The full list of 
genes can be found in the Supplemental Workbook.
The most commonly shared region of gain or loss in the Group I/muscle-enriched cases was 
a 2.5 MB region on 1p36.32, which spans PRDM16, TNFRSF14, C1orf93, and MMEL1. 
This region was lost in 8 of 12 Group I/muscle-enriched samples (consensus FDR = 0.01). 
This change was specific to this LMS subtype and there was no loss at 1p36.32 observed in 
the 1 Group II sample or in the 7 Group III samples. The PRDM16 gene has recently been 
shown to control a brown fat/skeletal muscle switch. Loss of PRDM16 from brown fat 
precursors promotes skeletal muscle differentiation and leads to elevated expression of 
muscle specific genes (Seale et al., 2008). Group I LMS showed high expression of a 
diverse set of muscle-associated genes, including genes expressed in smooth, cardiac, and 
skeletal muscle (including ACTG2, MYLK, PDLIM5), genes expressed primarily in cardiac 
and skeletal muscle (including CFL2, SLMAP), and genes expressed primarily in cardiac 
muscle (CASQ2). The loss of PRDM16 gene in most Group I cases suggests a potential 
etiology of the “muscle-enriched” pattern of gene expression observed in Group I tumors, 
which includes both genes expressed in smooth and skeletal/cardiac muscle, suggesting 
either that PRDM16 may have a role in expression of genes involved in skeletal, smooth, 
and cardiac muscle or a separate transcriptional regulatory factor may account for the 
increased expression of smooth muscle and cardiac muscle associated genes in Group I/
muscle-enriched LMS. MYOCD amplification has recently been shown to play an important 
role in LMS pathogenesis (Perot et al., 2009). In our study, a region on 17p11 containing 
MYOCD (as wellas MAP2K4) was amplified in 3 Group I/muscle-enriched tumors and the 
1 Group II sample.
Other cancer-associated genes that showed copy number gains in at least 6 of the Group I 
samples included: TCF12 (15q21), ABL2 (1q24), and the MET oncogene (7q31). MET 
overexpression has been previously reported in a variety of sarcomas, including alveolar soft 
part sarcoma (Jun et al., 2009), osteosarcoma, chondrosarcomas, and leiomyosarcoma (Rong 
et al., 1993). Copy number gain suggests a possible mechanism of MET overexpression in 
LMS. Additional cancer-associated genes that were lost in at least 6 Group I samples include 
the alveolar soft part sarcoma chromosome region, candidate 1 (ASPSCR; 17q25), BCL3 
(19q13), ERCC2 (19q13), FSTL3 (19p13), RB1 (13q14), STK11 (19p13), and TCF3 
(19p13) (An expanded table of cancer-associated genes with the copy number changes 
observed in our study is provided in the Supplemental Workbook).
There were no recurrent genomic changes seen in greater than 3 of the 7 Group III samples, 
and all of the changes seen in multiple Group III samples were also observed in multiple 
Group I/muscle-enriched samples. The only change involving a known gene that was shared 
in at least 3 of the 7 Group III cases was gain at 7q31.2, which includes the CAV-1 gene. 
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This region was also gained in 7 of 12 Group I/muscle-enriched cases and the 1 Group II 
case. Caveolin-1 is known to be expressed on smooth muscle and has been shown to activate 
the Akt pathway in an in vitro prostate cancer model (Li et al., 2003). The Akt pathway has 
been shown to play an important role in LMS (Hernando et al., 2007).
To determine whether the gene-expression defined molecular subtypes could be accurately 
predicted based solely on aCGH changes, we used 3 classification techniques: PAM, PAM-
FL, and KNN. The aCGH-based KNN classifier obtained a cross validation (CV) error rate 
of 4/19 (21%, corresponding to a permutation-based p value of 0.05), the PAM classifier 
obtained a CV error rate of 2/19 (11%), and the PAM-FL obtained a CV error rate of 1/19 
(5%). These findings demonstrate that the gene expression defined Groups I and III can be 
predicted with significant accuracy by aCGH changes alone. The PAM-FL centroid, which 
summarizes genomic changes in Group I relative to Group III is presented as Fig. S4.
C. Tissue Microarray Analysis
Based on the findings from gene expression profiling (which showed that Group I/muscle-
enriched LMS represented the most distinct molecular subtype) and aCGH (which showed 
that Group I/muscle-enriched LMS had the most recurrent regions of genomic gain and 
loss), we chose to focus our TMA analysis on evaluating the protein expression of genes 
with high levels of mRNA expression in the Group I/muscle-enriched LMS molecular 
subtype.
The protein expression of 5 markers highly and differentially expressed in Group I/muscle-
enriched LMS was examined on LMS TMAs. For the 377 LMS cases represented on the 
TMAs, there were evaluable results for all 5 stains for 275 cases. For the purposes of 
clinicopathologic analysis, we determined the sum total of positive staining markers for each 
case. Clinicopathologic data (including FNLCC histologic grade, mitotic count, necrosis, 
presence of CSF1 response protein expression signature (Beck et al., 2009a; Espinosa et al., 
2009b), and disease specific survival (DSS) were available for 124 of the 275 cases. 
Information on anatomic site (gynecological vs. non- gynecological) was available for 273 
samples.
The stains showed significant correlation with each other (all pairwise Spearman’s rho p < 
0.005) with a minimum correlation of 0.170 between ACTG2 and CASQ2 and a maximum 
correlation of 0.658 between ACTG2 and SLMAP (Fig. 3). 19% (51/275) of the cases 
showed coordinate expression of all 5 evaluable markers, similar to the 25% of cases present 
in the muscle enriched cluster by gene expression arrays.
The number of positive markers showed no association with site (mean positive markers = 
3.1 in both gynecological and non-gynecological LMS), no significant association with 
grade (mean positive markers = 3.1 in grade 1, 3.3 in grade 2, and 2.9 in grade 3; p=0.56), 
no significant association with mitotic figure count (p=0.335), and there was a trend for a 
negative association with the presence of necrosis (p=0.07). In a multivariate model 
incorporating the CSF1 response protein expression signature, the number of positive Group 
I/muscle-enriched markers, grade, tumor site (uterine vs. extra-uterine), necrosis and mitotic 
figures, the CSF1 response signature (summarizing the expression of 4 CSF1 response 
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signature-associated proteins) and the number of positive Group I/muscle-enriched markers 
were the only 2 significant predictors of survival, with the CSF1 response protein expression 
signature showing an association with poor outcome while expression of the Group I/muscle 
enriched markers was associated with a more favorable outcome (Table 1).
The findings from our TMA analysis demonstrate that the Group I/muscle-enriched markers 
show correlated protein expression, and the expression of Group I/muscle-enriched markers 
is associated with improved DSS independent of grade, mitotic figures, necrosis, site, and 
the CSF1 response signature.
DISCUSSION
LMS is an aggressive malignant neoplasm, and its molecular pathogenesis is poorly 
understood. Treatment options are limited, and there is a major clinical interest in gaining a 
better understanding of LMS pathogenesis to facilitate the development of targeted 
therapies.
Several prior studies have performed gene expression profiling on relatively small numbers 
(n=3–13) of LMS samples (Baird et al., 2005; Henderson et al., 2005; Nakayama et al., 
2007; Nielsen et al., 2002; Quade et al., 2004; Ren et al., 2003; Segal et al., 2003; 
Shmulevich et al., 2002; Skubitz and Skubitz, 2003). Due to the small number of cases in 
each study it is difficult to draw conclusions on the heterogeneity within LMS based on 
these data. Francis et al. performed gene expression profiling on 177 soft tissue tumors, 
including 40 LMS samples. They identified a distinct cluster of 11 LMSs that clustered 
together, while the remaining 29 LMS samples showed more heterogeneous patterns of gene 
expression (Francis et al., 2007). The distinct cluster of 11 LMS cases from this dataset were 
reported to show high expression levels of a group of muscle-associated genes, many of 
which were also identified as highly expressed in Group I/muscle-enriched LMS in our 
study (including CALD1, SLMAP, ACTG2, CFL2, MYLK, ACTA2, MBNL1, TPM1, 
PPP1R12A, DTNA, FZD6, PPP1R12A, CLIC4, CDC42EP3, BARD1, TPM1, RAB27A, 
MAP1B, EDIL). We find a similar muscle-enriched LMS cluster in our dataset and in the 
Baird dataset (Baird et al., 2005). Our findings and those from the literature suggest that 
multiple molecular subtypes of LMS exist and that the “muscle-enriched” subtype has been 
reproducibly identified in at least 2 of the largest datasets.
Several prior reports have looked at CGH changes in LMS. Meza-Zepeda et al. performed 
aCGH on 12 LMS samples and 7 gastrointestinal stromal tumors and observed that LMS 
showed more genomic losses than gains with the most frequent minimal regions of loss at 
10q21.3 and 13q14.2-q14.3, each detected in 9 of 12 LMS samples in their study (Meza-
Zepeda et al., 2006). In our study, we identified loss at 10q21.3 in 5 of 12 Group I/muscle-
enriched samples and in none of the Group II or III samples. We identified loss at 13q14.2 in 
6 of 12 Group I/muscle-enriched samples, 0 of 1 Group II samples, and 2 of 7 Group III 
samples. The common region of 13q14.2 that was lost in all 8 samples includes the RB1 
gene, a well-characterized tumor-suppressor whose loss has been shown to contribute to 
sarcomagenesis (Landis-Piwowar et al., 2008). Meza-Zepeda et al also noted loss at 
16q21.2-q22.1 in 6 of 12 samples and 1p36.32-p36.21 in 4 of 12 samples, which are both 
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changes we find in our study, specifically in Group I/muscle-enriched LMS. Larramendy et 
al evaluated 102 malignant fibrous histiocytomas (MFH) and 82 LMS cases by conventional 
comparative genomic hybridization (Larramendy et al., 2008) and identified 11 regions with 
significantly increased losses in LMS compared to MFH, including 1p36.1~pter (10% of 
LMS vs 1% of MFH), and 16qter (34% of LMS vs. 3% of MFH), both of which were 
identified as lost in most Group I/muscle-enriched LMS cases in our analysis. We note that 
the 1p36 region contains PRDM16 and the 16q24.3 region contains FANCA. To our 
knowledge, our study is the first to integrate aCGH data with gene expression analysis.
Prognosis in LMS is currently predicted using a combination of traditional clinicopathologic 
features (Kattan et al., 2002). There are currently no molecular biomarkers utilized in 
prognostication in LMS in clinical practice. Gene expression microarrays have been used to 
identify signatures to predict metastasis in LMS (Lee et al., 2004). Our group has previously 
identified macrophage infiltration (Lee et al., 2008) and the CSF1 response signature 
(Espinosa et al., 2009b) as predictors of poor prognosis in LMS. In the current study, we 
have identified protein markers from the Group I/muscle-enriched LMS subtype and 
demonstrated that their expression correlates with improved DSS. These findings suggest 
that despite showing increased genomic complexity, Group I/muscle-enriched LMS may be 
intrinsically less aggressive and more differentiated than other LMS subtypes. In a 
multivariate model incorporating traditional clinicopathologic features (size, grade, necrosis, 
site) as well as the CSF1 response signature and the Group I/muscle-enriched markers, we 
find that only the CSF1 response signature and the number of positive muscle-enriched 
markers emerged as significant predictors of survival, with the CSF1 response signature 
correlating with poor prognosis and the expression of Group I/muscle-enriched markers 
correlating with improved prognosis. These prognostic biomarkers, which can be measured 
with immunohistochemistry on paraffin embedded formalin fixed tissue, may prove useful 
for the clinical management of LMS. Ultimately, we hope that the characterization of 
distinct molecular subtypes in LMS will lead not only to the identification of clinically 
useful prognostic markers, but also to the development of treatments to target specific 
molecular aberrations observed in the subtypes.
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Figure 1. 
Unsupervised clustering of 51 LMS samples reveals 3 reproducible molecular subtypes. A) 
Unsupervised hierarchical clustering was performed on 51 LMS samples with 3038 genes 
that showed at least 1 standard deviation across the samples. The 20 samples that were also 
profiled for DNA copy number changes with aCGH are indicated by an asterisk. The 5 
paired primary-metastasis samples are indicated by a paired symbol (#,$,&,!,^). On the 
sample dendrogram, the Group I cases are heighted in red, Group II blue, and Group III 
green. The 2 cases that did not cluster into a group are indicated in black. Within the 
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heatmap, yellow indicates relatively increased expression, black indicates median 
expression, and blue indicates relatively decreased expression. B) Principal Component 
Analysis of the 51 LMS samples with 3038 genes. Each sample is represented in the figure 
by a colored box. The color indicates the clustering designation made by hierarchical 
clustering: red = Group I, blue = Group II, and Green = Group III. Most of the variance 
between the 3 groups is captured in the first two principal components. C) Sparse Principal 
Component Analysis. The 51 LMS samples were plotted against the sparse PCA coordinate 
1 (containing 45 genes) and sparse PCA coordinate 2 (containing 40 genes). Each sample is 
represented by a colored circle, and the color indicates the clustering designation made by 
hierarchical clustering: red = Group I, blue = Group II, green = Group III. Most of the 
variance between the 3 LMS molecular subtypes is explained by these 2 sparse principal 
components.
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Figure 2. 
Array Comparative Genomic Hybridization of 20 Leiomyosarcoma Samples. The 20 
samples are arranged along the y axis and ordered according to amount of DNA copy 
number changes. Chromosomal locations are indicated along the x axis. Copy number 
changes were called using the cghFLasso algorithm with an overall false discovery rate of 
0.10. Regions of genomic gain are indicated in red and loss in green. The proportion of 
genome showing gain or loss is indicated to the left of each row. The gene-expression 
defined molecular subtype is indicated on the colorbar on the left: red = Group I, blue = 
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Group II, green = Group III. The Group I cases show significantly increased regions of 
genomic gain/loss compared to the Group III cases (p=0.04).
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Figure 3. 
Protein Expression of Group I Markers on Leiomyosarcoma Tissue Microarray. We 
performed IHC for 5 markers that showed high levels of expression in Group I LMS in the 
gene expression analysis (CASQ2, MYLK, CFL2, SLMAP, ACTG2). The LMS TMAs 
contained a total of 377 samples that were scored as strong positive (bright red in the 
heatmap), weak positive (dull red), or negative (green). The antibodies are listed along the y 
axis and the 377 samples along the x axis. Missing data is indicated by white in the heatmap. 
Pictures of an LMS sample showing strong expression of all 5 stains is shown to the left of 
Beck et al. Page 18
Oncogene. Author manuscript; available in PMC 2010 August 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
the heatmap (magnification=200x). The five stains showed significantly correlated 
expression (all pairwise Spearman’s rho p < 0.005, with a minimum correlation of 0.17 
between ACTG2 and CASQ2 and a maximum correlation of 0.66 between ACTG2 and 
SLMAP).
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Table 1
Multivariate Cox Regression Analysis of Disease Specific Survival from LMS Tissue Microarray (n=124).
Multivariate Cox Regression Analysis of Disease Specific Survival
Wald HR [95% CI] P value
CSF1 response protein signature (Espinosa et al., 2009) 13.0 4.7 [2.0–10.9] < 0.001
Number of Positive Group I/muscle-enriched Markers 4.5 0.77 [0.6–0.98] 0.035
Site 1.8 0.35[0.1–1.6] 0.178
Mitotic Figures 0.8 1.3 [0.7–2.4] 0.371
Grade 0.32 1.3[0.6–2.5] 0.570
Necrosis 0.01 1.0 [0.5 – 2.2] 0.910
In the multivariate model, only the CSF1-response protein expression signature and the expression of Group-I/muscle-associated proteins showed a 
significant association with survival. In the table, the first column lists each variable included in the model, the second column lists the variable’s 
Wald test statistic, the third column lists the variable’s hazard ratio (HR) and 95% confidence interval (CI), and the fourth column lists the 
variable’s Wald test p value.
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